

# EPIRUS BIOPHARMACEUTICALS, INC.

## **FORM 8-K** (Current report filing)

Filed 08/02/12 for the Period Ending 08/01/12

Address	699 BOYLSTON ST 8TH FLOOR BOSTON, MA 02116
Telephone	(617) 600-3497
CIK	0001135906
Symbol	EPRSQ
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2012

**ZALICUS INC.**

(Exact name of Registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-51171**

(Commission File No.)

**04-3514457**

(IRS Employer Identification No.)

**245 First Street**

**Third Floor  
Cambridge, MA 02142**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(617) 301-7000**

**None**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Effective August 1, 2012, Zalicus Inc. (the "Company") terminated its equity distribution agreement (the "Agreement") with Wedbush Securities Inc. ("Wedbush") dated as of June 19, 2012. As previously reported, pursuant to the terms of the Agreement, the Company could offer and sell shares of its common stock, \$0.001 par value per share (the "Common Stock"), having an aggregate offering price of up to \$15.0 million from time to time to or through Wedbush. Through August 1, 2012, the Company had sold an aggregate of 13,091,957 shares of Common Stock pursuant to the Agreement for aggregate gross proceeds of approximately \$15.0 million. Aggregate commissions paid to Wedbush pursuant to the Agreement were approximately \$300,000.

Further details regarding the terms of the Agreement are set forth in the Company's Current Report on Form 8-K dated June 19, 2012, which is incorporated herein by reference.

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Zalicus Inc.

By: /s/Justin Renz

Name: Justin Renz

Title: Executive Vice President, Chief Financial  
Officer and Treasurer

Dated: August 2, 2012

---